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PURPOSE:  To evaluate changes in tumor vascularization parameters based on
contrast-enhanced ultrasound (CEUS) quantification criteria of at least one visible
liver metastasis as an early predictor of non-response to chemotherapy, including
bevacizumab for colorectal cancer (CRC) liver metastases.
MATERIALS AND METHODS:  This multicenter prospective study included patients
who received first-line bevacizumab-based chemotherapy. Tumor enhancement
measured using CEUS within one liver metastasis and in relation to the surrounding
healthy liver was quantified within 8 days before the first infusion of bevacizumab
(E0), 24 hours after the end of the first infusion of bevacizumab (E1), in the 24 hours
before the 2nd and 3 rd infusion of bevacizumab on day 15 (E2) and day 30 (E3),
respectively, and after 2 months of treatment (E4). Endpoints were tumor response
using RECIST criteria at 2 months, progression-free survival (PFS) and overall survival
(OS).
RESULTS:  Among the 137 patients included in this study, 109 were analyzed. Only
CEUS parameters calculated in relation to healthy liver were significant. High wash-in
and wash-out rates at baseline were significantly associated with a better tumor
response. Increases over time E2-E0 and E3-E0 for peak enhancement were
significantly associated with shorter progression-free survival. Increases over time E2-
E0 and E3-E0 for peak enhancement and wash-in area under the curve were
significantly associated with a shorter overall survival.
CONCLUSION:  This large study demonstrated that early dynamic changes in the
vascularity of liver metastases evaluated by quantified CEUS are associated with
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